FWBI - First Wave surges ~30% on patent filing for adrulipase's delayed release formulation
- First Wave BioPharma ( NASDAQ: FWBI ) said it filed a U.S. provisional patent application related to composition of matter improvements for enhancing adrulipase's delayed release profile.
- This filing adds to the intellectual property (IP) portfolio related to adrulipase, which includes patent applications governing adrulipase formulation and methods of use and use of enteric formulations to deliver adrulipase, the company added.
- "Enhancing the IP portfolio protecting adrulipase and the microgranule drug delivery formulation is an important value-building opportunity for First Wave as we prepare to soon initiate the Phase 2 clinical trial of adrulipase in exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis," said First Wave President and CEO James Sapirstein.
- The company added that in vitro data suggests that the microgranule drug delivery formulation offers improved protection against the acidic pH in the stomach followed by the rapid release of adrulipase in the small intestine where the drug is expected to mix with food and deliver its therapeutic benefit.
- In addition, the research indicates that the formulation has the potential to decrease the number of pills a patient would need to take.
- FWBI +28.51% to $5.68 premarket Jan. 25
For further details see:
First Wave surges ~30% on patent filing for adrulipase's delayed release formulation